Headline
The latest stories from AHA Today.
The AHA’s opposition to UnitedHealthcare’s now-delayed policy on emergency coverage was picked up by the media and was mentioned in numerous publications, including The New York Times, USA Today, Modern Healthcare, Minneapolis Star Tribune, as well as a local TV interview with AHA President and CEO…
The Occupational Safety and Health Administration issued an emergency temporary standard for occupational exposure to COVID-19 that requires certain health care employers to help protect their workers in settings where suspected or confirmed COVID-19 patients are treated.
The Health Resources and Services Administration awarded 56 organizations $22 million in grants to train graduate-level students of social work, psychology, and other behavioral and mental health disciplines to work with youth and other vulnerable populations at risk for behavioral health disorders…
Johnson & Johnson said the Food and Drug Administration agreed to extend the expiration date for its COVID-19 vaccine by six weeks.
After concerns raised by the AHA and other health groups, UnitedHealthcare delayed plans to deny coverage for emergency department claims the insurer deems non-emergent. The policy was to take effect July 1.
During the COVID-19 pandemic, Grand Rapids, Mich-based Spectrum Health used the full scope of its resources to enable easy vaccine access, keep its communities informed, maintain and expand access in ZIP codes bearing the brunt of infections, and fuel innovation.
The National Urban League, a strategic partner of AHA, June 15-16 is hosting its annual Legislative Policy Conference as a free virtual event.
Health care providers participating in the Centers for Disease Control and Prevention’s COVID-19 Vaccination Program must administer the vaccines at no cost to recipients, the Department of Health and Human Services reminded providers and health plans in a letter.
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced.
Medicare will pay about $75 per dose to administer COVID-19 vaccines in a Medicare beneficiary’s home, the Centers for Medicare & Medicaid Services announced.